|
Botta C., Perez C., Larrayoz M., Puig N., Cedena M.T., Termini R., Goicoechea I., Rodriguez S., Zabaleta A., Lopez A., Sarvide S., Blanco L., Papetti D.M., Nobile M.S., Besozzi D., Gentile M., Correale P., Siragusa S., Oriol A., González-Garcia M.E., Sureda A., de Arriba F., Rios Tamayo R., Moraleda J.M., Gironella M., Hernandez M.T., Bargay J., Palomera L., Pérez-Montaña A., Goldschmidt H., Avet-Loiseau H., Roccaro A., Orfao A., Martinez-Lopez J., Rosiñol L., Lahuerta J.J., Blade J., Mateos M.V., San-Miguel J.F., Martinez Climent J.A., Paiva B. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance. Nature Communications. December 2023. 14. 10.1038/s41467-023-41562-6
AÑO: 2023; IF: 14.7
|
37730678
|
Tilmont R, Yakoub-Agha I, Eikema DJ, Zinger N, Haenel M, Schaap N, Arroyo CH, Schuermans C, Besemer B, Engelhardt M, Kuball J, Michieli M, Schub N, Wilson KMO, Bourhis JH, Mateos MV, Rabin N, Jost E, Kroger N, Moraleda JM, Za T, Hayden PJ, Beksac M, Mclornan D, Schonland S, Manier S. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2023 Nov;58(11):1182-1188. doi: 10.1038/s41409-023-02048-7. Epub 2023 Aug 5. PubMed PMID: 37543712; PubMed Central PMCID: PMC10622318.
AÑO: 2023; IF: 4.5
|
|
Puig N, Contreras MT, Agullo C, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Inigo MB, Sureda A, Hernandez MT, de la Rubia J, Gonzalez-Calle V, Krsnik I, Cabanas V, Palomera L, Moraleda JM, Bargay J, Cedena MT, Paiva B, Rosinol L, Blade J, San Miguel J, Lahuerta JJ, Mateos MV. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022 Jun 14;6(11):3234-3239. doi: 10.1182/bloodadvances.2021006762. PubMed PMID: 35157768; PubMed Central PMCID: PMC9198943.
AÑO: 2022; IF: 7.5
|
|
Fernandez-Santos ME, Garcia-Arranz M, Andreu EJ, Garcia-Hernandez AM, Lopez-Parra M, Villaron E, Sepulveda P, Fernandez-Aviles F, Garcia-Olmo D, Prosper F, Sanchez-Guijo F, Moraleda JM, Zapata AG. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome. Front Immunol. 2022 Jun 9;13:918565. doi: 10.3389/fimmu.2022.918565. eCollection 2022. PubMed PMID: 35812460; PubMed Central PMCID: PMC9261977.
AÑO: 2022; IF: 7.3
|
|
Lankester AC, Neven B, Mahlaoui N, von Asmuth EGJ, Courteille V, Alligon M, Albert MH, Serra IB, Bader P, Balashov D, Beier R, Bertrand Y, Blanche S, Bordon V, Bredius RG, Cant A, Cavazzana M, Diaz-de-Heredia C, Dogu F, Ehlert K, Entz-Werle N, Fasth A, Ferrua F, Ferster A, Formankova R, Friedrich W, Gonzalez-Vicent M, Gozdzik J, Gungor T, Hoenig M, Ikinciogullari A, Kalwak K, Kansoy S, Kupesiz A, Lanfranchi A, Lindemans CA, Meisel R, Michel G, Miranda NAA, Moraleda J, Moshous D, Pichler H, Rao K, Sedlacek P, Slatter M, Soncini E, Speckmann C, Sundin M, Toren A, Vettenranta K, Worth A, Yesilipek MA, Zecca M, Porta F, Schulz A, Veys P, Fischer A, Gennery AR. Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort. J Allergy Clin Immunol. 2022 May;149(5):1744-1754.e8. doi: 10.1016/j.jaci.2021.10.017. Epub 2021 Oct 27. PubMed PMID: 34718043.
AÑO: 2022; IF: 14.2
|